Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

Kambiz Rahbar; Markus Essler; Kim M. Pabst; Matthias Eiber; Christian la Fougère; Vikas Prasad; Philipp Rassek; Ergela Hasa; Helmut Dittmann; Ralph A. Bundschuh; Wolfgang P. Fendler; Milena Kurtinecz; Anja Schmall; Frank Verholen; Oliver Sartor

doi:10.2967/jnumed.122.264456

Research ArticleBRIEF COMMUNICATION

Open Access

Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment: The RALU Study

Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor

Journal of Nuclear Medicine April 2023, 64 (4) 574-578; DOI: https://doi.org/10.2967/jnumed.122.264456

Kambiz Rahbar

1Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Markus Essler

2Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim M. Pabst

3Department of Nuclear Medicine, German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

4Department of Nuclear Medicine, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian la Fougère

5Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vikas Prasad

6Department of Nuclear Medicine, University of Ulm, Ulm, Germany;

7International Centers for Precision Oncology Foundation, Ravensburg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philipp Rassek

1Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ergela Hasa

4Department of Nuclear Medicine, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Helmut Dittmann

5Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ralph A. Bundschuh

8Department of Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

3Department of Nuclear Medicine, German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Milena Kurtinecz

9Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anja Schmall

10Bayer Consumer Care, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank Verholen

10Bayer Consumer Care, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oliver Sartor

11Tulane Cancer Center, Tulane Medical School, New Orleans, Louisiana

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 4

April 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment: The RALU Study

Journal of Nuclear Medicine Apr 2023, 64 (4) 574-578; DOI: 10.2967/jnumed.122.264456

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment: The RALU Study

Journal of Nuclear Medicine Apr 2023, 64 (4) 574-578; DOI: 10.2967/jnumed.122.264456

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

Google Scholar

Keywords

targeted α-therapy
223Ra
177Lu-PSMA
metastatic castration-resistant prostate cancer
real-world practice

Main menu

User menu

Search

Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment: The RALU Study

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords